All In MedTech

Device Trial Radar · NCT05442203

Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease

Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 7, 2022

Primary completion

Jul 2025

Study completion Jul 2025

Sponsor

Lead sponsor
Tempus AINot on our public-company list
Sponsor type
Industry
First posted
Jul 1, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atrial fibrillation is an abnormal beating of the heart that can lead to stroke or heart failure. Structural heart diseases are conditions that affect the heart valves or heart muscle and can cause permanent heart damage if left untreated. Sometimes people have atrial fibrillation or structural heart disease and do not know it. The purpose of this study is to evaluate two devices that can predict who has or may develop atrial fibrillation or structural heart disease based on the results of an electrocardiogram.

Conditions

  • Atrial Fibrillation
  • Structural Heart Disease

Interventions

  • Zio Patch MonitorDevice

    Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.

  • EchocardiogramDevice

    Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive-predictive value (PPV) of the AF device at six monthsTime frame: 12 months
  2. Positive-predictive value (PPV) of the SHD device at six monthsTime frame: 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Corewell Health

    Grand Rapids, Michigan

  • TriHealth

    Cincinnati, Ohio

  • Geisinger Medical Center

    Danville, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.